Back to homepage

Haematology and Oncology

Standard care and investigational drugs in the treatment of myelofibrosis

Authors: Daniela Barraco MD, Margherita Maffioli MD, Francesco Passamonti MD

This article reviews the therapeutic landscape in myelofibrosis, which has
significantly improved, and emerging drugs with different
target pathways, alone or in combination with ruxolitinib.
promising.

More▸

Palbociclib in metastatic breast cancer: current evidence and real-life data

Authors: Francesco Serra MD, Pietro Lapidari MD, Erica Quaquarini MD, Barbara Tagliaferri MD, Federico Sottotetti MD, Raffaella Palumbo MD, PhD

This review summarizes the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice.

More▸

Immunotherapy in inoperable stage III non-small cell lung cancer: a review

Authors: Natasha A Jain MD, Gregory A Otterson MD

This article summarizes the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III nonsmall cell lung cancer.

More▸

Second-line treatment options in hepatocellular carcinoma

Authors: Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

More▸

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

Authors: Vincenzo Accurso MD, Marco Santoro MD, Salvatrice Mancuso MD, Marisante Napolitano MD, Florinda Di Piazza MD, Antonio Russo MD, Sergio Mario Siragusa MD

This case report presents initial experience with a patient affected by primary myelofibrosis, retreated with ruxolitinib after a 3-month suspension of
therapy due to clinical decision.

More▸